BioXcel Therapeutics (BTAI) Total Non-Current Liabilities (2022 - 2026)

BioXcel Therapeutics' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $132.9 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 5.89% year-over-year to $132.9 million; the TTM figure through Mar 2026 stood at $132.9 million (up 5.89% YoY), while the FY2025 annual figure was $138.6 million, up 11.04% from the prior year.
• Total Non-Current Liabilities was $132.9 million for Q1 2026 at BioXcel Therapeutics, down from $138.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $139.0 million in Q3 2023 to a low of $82.0 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $126.6 million across 5 years, with a median of $130.1 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities soared 61.19% in 2023, then decreased 6.38% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $126.7 million in 2022, then gained by 1.24% to $128.3 million in 2023, then retreated by 2.73% to $124.8 million in 2024, then gained by 11.04% to $138.6 million in 2025, then fell by 4.14% to $132.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $132.9 million (Q1 2026), $138.6 million (Q4 2025), and $130.1 million (Q3 2025), per Business Quant data.